What's Happening?
The European Commission has published updates to the lists of harmonized standards for medical devices under the Medical Device Regulation (MDR) and In Vitro Diagnostic Regulation (IVDR). These updates, detailed in Implementing Decisions (EU) 2026/1231
and 2026/1313, cover various technical areas such as biological evaluation, medical electrical equipment, and symbols used in manufacturer information. The updates include significant changes to the EN ISO 10993 series, which is crucial for the biological evaluation of medical devices. Manufacturers can now rely on these harmonized standards to demonstrate compliance with safety and performance requirements, although adherence remains voluntary. The updates also introduce a new symbol for the Authorized Representative, affecting labeling and packaging.
Why It's Important?
These updates are significant for manufacturers as they provide a framework for demonstrating compliance with European safety and performance standards. By adhering to these harmonized standards, manufacturers can benefit from a presumption of conformity, simplifying the regulatory process. This is particularly important for companies exporting medical devices to the European Union, as it can streamline market entry and reduce compliance costs. The changes also reflect the latest state of the art in medical device safety, ensuring that products meet high safety standards. This can enhance consumer trust and potentially increase market competitiveness for compliant manufacturers.
What's Next?
Manufacturers will need to assess the impact of these updates on their technical documentation and compliance strategies. The transitional period until December 2027 for certain standards allows time for adaptation. Companies may need to update their labeling and packaging to align with the new Authorized Representative symbol by 2031. As the updates are voluntary, manufacturers choosing not to adopt them must ensure alternative compliance methods meet equivalent safety levels. This could involve additional testing or documentation to prove conformity, potentially increasing costs and time to market.
